European Commission approves Gilead’s remdesivir for COVID-19The European Commission has conditionally approved Gilead’s remdesivir for treatment of COVID-19, the first drug officially cleared for use against Share XEuropean Commission approves Gilead’s remdesivir for COVID-19https://pharmaphorum.com/news/european-commission-approves-gileads-remdesivir-for-covid-19/
US government buys most of world’s supply of COVID-19 drug remdesivirThe US government has acquired most of the global supply of Gilead’s COVID-19 drug remdesivir until September as Share XUS government buys most of world’s supply of COVID-19 drug remdesivirhttps://pharmaphorum.com/news/us-government-buys-most-of-worlds-supply-of-covid-19-drug-remdesivir/
COVID-19 drug remdesivir recommended for EU approvalThe EMA’s human medicines committee (CHMP) has recommended granting a conditional marketing authorisation to Gilead’s COVID-19 treatment remdesivir Share XCOVID-19 drug remdesivir recommended for EU approvalhttps://pharmaphorum.com/news/covid-19-drug-remdesivir-recommended-for-eu-approval/
Gilead to acquire half of cancer biotech Pionyr for $275mGilead has announced it is to acquire nearly half of the cancer drug biotech Pionyr, with an exclusive Share XGilead to acquire half of cancer biotech Pionyr for $275mhttps://pharmaphorum.com/news/gilead-to-acquire-cancer-biotech-pionyr/
AZ reportedly mulls biggest-ever pharma merger with GileadAlmost exactly six years ago AstraZeneca managed to convince investors to reject a takeover bid from Pfizer – Share XAZ reportedly mulls biggest-ever pharma merger with Gileadhttps://pharmaphorum.com/news/az-reportedly-mulls-biggest-ever-pharma-merger-with-gilead/
Mereo raises $70m as TIGIT cancer drug progresses in clinicMereo BioPharma has raised $70m to develop its next-generation anti-TIGIT cancer checkpoint inhibitor drug. The finance round was led by OrbiMed and Share XMereo raises $70m as TIGIT cancer drug progresses in clinichttps://pharmaphorum.com/news/mereo-raises-70m-as-tigit-cancer-drug-progresses-in-clinic/
Gilead’s remdesivir could be $7.7bn blockbuster – analystAn influential analyst has upped his previously cautious assessment of the sales potential of Gilead’s COVID-19 drug remdesivir, saying Share XGilead’s remdesivir could be $7.7bn blockbuster – analysthttps://pharmaphorum.com/news/gileads-remdesivir-could-be-7-7bn-blockbuster-analyst/
Coronavirus news roundup – 29/05/2020A series of vaccines and drugs are being fast-tracked through the big pharma pipeline as part of a Share XCoronavirus news roundup – 29/05/2020https://pharmaphorum.com/views-and-analysis/coronavirus-news-roundup-29-05-2020/
UK okays early access to Gilead’s remdesivir in seriously ill COVID-19 patientsThe UK’s drugs regulator has said that there is enough evidence to support the use of Gilead’s COVID-19 Share XUK okays early access to Gilead’s remdesivir in seriously ill COVID-19 patientshttps://pharmaphorum.com/news/uk-okays-early-access-to-gileads-remdesivir-in-seriously-ill-covid-19-patients/
